In this study, inhibitory kinetics of Nuciferine and Methyl Ganoderate extrated from Lotus Leaves and Ganoderma lucidum on Mucor miehei Lipase were studied first. The molecular structure of Nuciferine and Methyl Ganoderate were determined. The inhibitory effects of two extracts on lipase were reversible, with the IC₅₀ values of 0.194 and 0.332 mg/mL, respectively. The inhibition kinetic analysis by Lineweaver-Burk plots showed that they were a mixed-type inhibitor of lipase, with inhibition constants K_I of 0.16 and 0.29 mg/mL, and K_IS of 0.36 and 0.49 mg/mL, respectively. Results of spectral analysis showed that the UV absorption and the molecule fluorescence spectrum of the lipase hydrolyzate were significantly decreased after the inhibitor was added. The molecular docking further suggested that the interaction site between the active substance and inhibitor was located in an α-helix and a β-sheet of the lipase, and the lipase active site was interfered by the inhibitor near the cap structure. In addition, the proliferation and differentiation of 3 T3-L1 preadipocytes were inhibited by two extracts. Total triglycerides and cholesterol were significantly reduced in the cells. The results confirmed that Nuciferine and Methyl Ganoderate can be used as potential obesity treatment drugs.

在这项研究中，抑制动力学荷叶碱和甲基Ganoderate从萃取荷叶和灵芝对毛霉脂肪酶进行了首次研究。确定了Nuciferine和灵芝酸甲酯的分子结构。两种提取物对脂肪酶的抑制作用是可逆的，IC ₅₀值分别为0.194和0.332 mg / mL。通过Lineweaver-Burk图进行的抑制动力学分析表明，它们是脂肪酶的混合型抑制剂，抑制常数K _I为0.16和0.29 mg / mL，K _IS分别为0.36和0.49 mg / mL。光谱分析结果表明，加入抑制剂后，脂肪酶水解产物的紫外吸收和分子荧光光谱明显降低。分子对接进一步表明，活性物质和抑制剂之间的相互作用位点位于脂肪酶的α-螺旋和β-折叠中，并且脂肪酶活性位点受到帽结构附近的抑制剂的干扰。此外，两种提取物抑制了3个T3-L1前脂肪细胞的增殖和分化。细胞中的总甘油三酸酯和胆固醇显着降低。结果证实，核苷和灵芝酸甲酯可用作潜在的肥胖症治疗药物。